Histogenics Corporation Form 10-K Summary
Filing and period: Annual report for the fiscal year ended December 31, 2016, filed March 16, 2017. The provided filing is for Histogenics Corporation, not Ocugen, Inc.; the requested “2016 Q4” period is covered only as part of the full-year Form 10-K.
Business Context and Reporting Period
Histogenics was a clinical-stage regenerative medicine company focused on musculoskeletal tissue repair. Its lead product candidate, NeoCart, was an autologous tissue-engineered implant for cartilage damage in the knee. NeoCart was not approved for sale, and the company had no commercial product revenue.
- NeoCart was being evaluated in a 245-patient Phase 3 trial under an FDA Special Protocol Assessment.
- Enrollment reached 196 patients at December 31, 2016, with 34 eligible sites.
- Management expected to complete enrollment by the end of the second quarter of 2017, obtain 12-month data in mid-2018, and submit a BLA in the second half of 2018 if results were positive.
- The company had 47 full-time employees at year-end.
Financial Performance and Key Metrics
| Metric | 2016 | 2015 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $21.6 million | $23.2 million | Down 7% |
| General and administrative expense | $8.5 million | $8.3 million | Up 3% |
| Total operating expenses | $30.3 million | $31.8 million | Down 5% |
| Net loss | $16.2 million | $32.0 million | Improved by $15.8 million |
| Basic loss per share | $0.97 | $2.42 | Improved |
| Cash used in operating activities | $25.7 million | $30.0 million | Down 14% |
| Cash and cash equivalents at year-end | $31.9 million | $30.9 million | Up $1.0 million |
| Equipment loan outstanding | $0.8 million | $1.3 million | Down $0.6 million |
| Accumulated deficit | $181.8 million | $165.6 million | Increased $16.2 million |
Operating margin and net margin were not meaningful because the company generated no revenue. The reported 2016 net loss benefited materially from a $17.5 million non-cash gain from the change in fair value of warrant liabilities. This was partly offset by $3.1 million of warrant expense and a $0.2 million write-off of in-process research and development.
Financing activities provided $27.0 million of cash, primarily from a September 2016 private placement that generated $27.6 million of net proceeds. The transaction included common stock, Series A convertible preferred stock and warrants. At year-end, the company had $13.2 million of warrant liability and $3.4 million of accrued amounts payable to Intrexon, including $3.0 million classified as long term.
Material Changes Versus the Prior Comparable Period
- R&D expense decreased by $1.7 million, primarily because of lower consulting costs, lower raw-material purchases and lower patient-recruitment costs; these savings were partly offset by increased Phase 3 enrollment costs.
- Phase 3 enrollment increased by approximately 40% in 2016, to 82 patients from 59 in 2015.
- Net loss improved substantially, largely because of the non-cash warrant fair-value gain and lower operating expenses.
- Cash used in operations declined by $4.3 million, while year-end cash remained approximately $31.9 million after the private placement.
- The company completed FDA-related steps for internally produced collagen and its collagen scaffold comparability strategy. Scaffold transition and adhesive-component qualification were expected to continue in 2017.
- The company wrote off the remaining $0.2 million of acquired IPR&D because it had no plans to advance that technology.
- Common shares outstanding increased materially through the private placement and conversion of Series A preferred stock; additional dilution could arise from outstanding warrants, preferred stock and options.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management estimated that existing cash would fund projected operations into approximately mid-2018, or into the middle of the third quarter of 2018 if expenses were reduced or deferred. Additional capital was required to complete the BLA process and commercialize NeoCart.
- The primary value driver was completion and success of the NeoCart Phase 3 trial. Early-stage results did not assure Phase 3 success or FDA approval.
- NeoCart remained subject to extensive FDA requirements, including clinical efficacy, manufacturing controls, facility inspections and FDA approval of comparability for transferred raw materials.
- Enrollment delays, patient attrition, adverse clinical outcomes, manufacturing failures, supply interruptions or additional FDA-required studies could increase costs and delay or prevent approval.
- The company had no approved products, no product sales and a history of recurring losses and negative operating cash flow.
- Additional financing could be unavailable or costly and could dilute existing stockholders or impose restrictive debt covenants.
- The private-placement warrants were classified as a liability and remeasured through earnings, creating potentially significant volatility in reported results that was not representative of operating cash flow.
- The company was subject to a Nasdaq notice for failure to maintain the $50 million minimum market value of listed securities, with a stated deadline of May 17, 2017 to regain compliance or face potential delisting proceedings.
- There were no pending or threatened legal proceedings disclosed at year-end. Minimum operating lease commitments totaled $5.7 million, including $2.3 million due in 2017.
- The company reported effective disclosure controls and internal control over financial reporting as of December 31, 2016; the independent auditor did not express an opinion on internal control effectiveness.
Most Important Facts for Investors to Verify
- Confirm that the filing belongs to Histogenics Corporation rather than Ocugen, Inc., and verify the intended issuer and reporting period.
- Review subsequent filings for completion of NeoCart Phase 3 enrollment, trial results, BLA submission and FDA feedback.
- Reconcile the cash runway estimate with actual quarterly cash burn and determine when additional financing became necessary.
- Analyze the private-placement warrant terms, potential share dilution and the effect of recurring fair-value remeasurement on earnings.
- Verify the status of FDA comparability approvals and manufacturing readiness for collagen, the scaffold and CT3 adhesive components.
- Check Nasdaq listing compliance and any subsequent reverse split, financing, delisting or capital-structure actions.
- Review Intrexon obligations, accrued balances, future milestones and royalty or profit-sharing terms.
- Assess the company’s ability to fund operations through BLA filing and commercialization, given the lack of revenue and accumulated deficit.